02/14/2023

Legislation to Increase PBM Transparency and Lower Out-of-Pocket Costs Introduced in Congress

Both chambers of the United States Congress are working on a top healthcare priority for the session —protecting patients from high out-of-pocket drug costs and pharmacy benefit manager (PBM) practices that could reduce access and adherence to treatments. 

In the Senate, Senators Maria Cantwell (D-WA) and Chuck Grassley (R-IA) recently introduced the Pharmacy Benefit Manager Transparency Act of 2023 (S.127), legislation that would incentivize fair and transparent PBM practices, prohibit unfair or deceptive pricing practices, and mandate transparency. The Association for Clinical Oncology (ASCO) endorses this timely legislation and will continue to work with bill sponsors to shed light on opaque PBM practices that can negatively impact individuals with cancer.

READ MORE